黄芩素靶向GTP酶介导的自噬以清除对mTORC1抑制耐药的肝肿瘤起始干细胞样细胞
研究针对肝癌中mTORC1抑制剂耐药问题,发现黄芩素(BC)能选择性增敏CD133+肿瘤起始干细胞样细胞(TIC)及Huh7细胞,而不影响原代肝细胞。机制上BC竞争性抑制SAR1B鸟苷三磷酸酶GTP结合从而抑制自噬,与mTORC1抑制剂协同促细胞死亡,SAR1B表达可逆转该效应。
要点
- 黄芩素选择性增敏CD133+ TIC和Huh7细胞,对原代肝细胞无此作用。
- 黄芩素竞争性抑制SAR1B GTP结合,抑制mTORC1抑制剂诱导的自噬。
- SAR1B表达可逆转黄芩素增敏效应,SAR1B敲低可模拟该效应。
核心结论
- SAR1B是耐药肝TIC和HCC细胞的靶点,黄芩素通过抑制SAR1B介导的自噬增敏mTORC1抑制。
研究设计与样本
- 基础研究,使用从小鼠和人肝肿瘤分离的CD133+ TIC、人HCC细胞系Huh7、小鼠和人原代肝细胞及患者来源异种移植模型。
主要发现
- 黄芩素选择性增敏TIC和Huh7细胞,但不增敏小鼠和人原代肝细胞。
- 黄芩素竞争性抑制SAR1B的GTP结合,抑制mTORC1抑制剂诱导的自噬。
- 黄芩素与mTORC1抑制剂协同促进TIC和Huh7球体形成及HCC患者来源异种移植模型中的细胞死亡。
- SAR1B表达可逆转黄芩素诱导的增敏,SAR1B敲低可模拟该效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance. The CD133+ tumor-initiating stem cell-like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search of a compound that rescinds resistance of TICs to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC), which selectively chemosensitizes TICs and the human hepatocellular carcinoma (HCC) cell line Huh7 cells but not mouse and human primary hepatocytes. Nanobead pull-down and mass-spectrometric analysis, biochemical binding assay, and three-dimensional computational modeling studies reveal BC's ability to competitively inhibit guanosine triphosphate binding of SAR1B guanosine triphosphatase, which is essential for autophagy. Indeed, BC suppresses autophagy induced by an mTORC1 inhibitor and synergizes cell death caused by mTORC1 inhibition in TIC and Huh7 spheroid formation and in the patient-derived xenograft model of HCC. The BC-induced chemosensitization is rescued by SAR1B expression and phenocopied by SAR1B knockdown in cancer cells treated with a mTORC1 inhibitor. Conclusion: These results identify SAR1B as a target in liver TICs and HCC cells resistant to mTORC1 inhibition.
引用
- Wu R, Murali R, Kabe Y, et al. Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology. 2018. PMID: 29729190. doi:10.1002/hep.30071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。